A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer.

Trial Profile

A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Ribociclib (Primary) ; Everolimus; Exemestane
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 05 Apr 2017 Results of a pooled analysis assessing preliminary clinical activity in patients from three clinical trials (NCT01872260, NCT01857193 and NCT02088684), presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 21 Feb 2017 Planned End Date changed from 1 Dec 2017 to 28 Sep 2018.
    • 21 Feb 2017 Planned primary completion date changed from 1 Dec 2017 to 28 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top